Objective: To investigate the prognostic factors in chemorefractory colorectal cancer liver metastasis(CRCLM)patients treated by transarterial chemoembolization(TACE) and sustained hepatic arterial infusion chemotherapy(HAIC).Methods: Between 2006 and 2015, 162 patients who underwent 763 TACE and HAIC in total were enrolled in this retrospective study, including 110 males and 52 females, with a median age of 60(range, 26–83) years.Prognostic factors were assessed with Log-rank test, Cox univariate and multivariate analyses.Results: The median survival time(MST) and median progression-free survival(PFS) of the 162 patients from first TACE/HAIC were 15.6 months and 5.5 months respectively. Normal serum carbohydrate antigen 19-9(CA19-9, <37 U/m L)(P<0.001) and carbohydrate antigen 72-4(CA72-4, <6.7 U/m L)(P=0.026), combination with other local treatment(liver radiotherapy or liver radiofrequency ablation)(P=0.034) and response to TACE/HAIC(P<0.001) were significant factors related to survival after TACE/HAIC in univariate analysis. A multivariate analysis revealed that normal serum CA19-9(P<0.001), response to TACE/HAIC(P<0.001) and combination with other local treatment(P=0.001) were independent factors among them.Conclusions: Our findings indicate that serum CA19-9 <37 U/m L and response to TACE/HAIC are significant prognostic indicators for this combined treatment, and treated with other local treatment could reach a considerable survival benefit for CRCLM. This could be useful for making decisions regarding the treatment of CRCLM. Objective: To investigate the prognostic factors in chemorefractory colorectal cancer liver metastasis (CRCLM) patients treated by transarterial chemoembolization (TACE) and sustained hepatic arterial infusion chemotherapy (HAIC). Methods: Between 2006 and 2015, 162 patients who underwent 763 TACE and HAIC in total were enrolled in this retrospective study, including 110 males and 52 females, with a median age of 60 (range, 26-83) years. Prognostic factors were assessed with Log-rank test, Cox univariate and multivariate analyzes. Results: The median Normal serum carbohydrate antigen 19-9 (CA19-9, <37 U / m L) was obtained from the first TACE / HAIC for 15.6 months and 5.5 months respectively (P <0.001) and carbohydrate antigen 72-4 (CA72-4, <6.7 U / m L) (P = 0.026), combination with other local treatment (liver radiotherapy or liver radiofrequency ablation) TACE / HAIC (P <0.001) were significant factors related to su rvival after TACE / HAIC in univariate analysis. A multivariate analysis revealed that normal serum CA19-9 (P <0.001), response to TACE / HAIC (P <0.001) and combination with other local treatment They.Conclusions: Our findings indicate that serum CA19-9 <37 U / m L and response to TACE / HAIC are significant prognostic indicators for this combination treatment, and treated with other local treatment could reach a considerable survival benefit for CRCLM. This could be useful for making decisions regarding the treatment of CRCLM.